Sample analyzer, method and computer-readable storage medium for detecting cryptococcus

Through the optical detection technology of the sample analyzer, the samples are processed using hemolytic reagents and fluorescent reagents, and scattered light and fluorescence information are collected to accurately distinguish and count cryptococcal particle populations, which solves the existing cryptococcal detection methods with low sensitivity and high false positive rate. Problem, fast and accurate detection of cryptococcus.

CN113125392BActive Publication Date: 2024-11-19SHENZHEN MINDRAY BIO MEDICAL ELECTRONICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201911415630.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-12-31
Publication Date
2024-11-19
Estimated Expiration
2040-05-05

AI Technical Summary

Technical Problem

The existing Cryptococcus detection methods have low sensitivity and high false positive rate, high detection cost, and complex detection process, making it difficult to quickly and accurately diagnose Cryptococcus infection.

Method used

Using a sample analyzer, the sample is absorbed through the sampling device and mixed with hemolytic reagent and fluorescent reagent. The optical detection device collects scattered light and fluorescent information, distinguishes and counts the cryptococcal particle population through the processor, and determines whether there is cryptococcal in the sample. Infect.

Benefits of technology

It realizes rapid and accurate detection of Cryptococcus, reduces false positive rates, simplifies the detection process, and improves detection efficiency and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113125392B_ABST
    Figure CN113125392B_ABST
Patent Text Reader

Abstract

The present application discloses a sample analyzer, method and computer-readable storage medium for detecting cryptococci in a sample. The sample analyzer includes: a sampling device, a sample preparation device, an optical detection device and a control device, which is electrically connected to the optical detection device and includes a processor and a storage medium storing a computer program, wherein the control is configured to perform the following steps when the computer program is executed by the processor: obtaining at least two types of light intensity information in the optical information from the optical detection device, and distinguishing the cryptococcal particle group in the sample to be tested based on the at least two types of light intensity information. The present invention utilizes the characteristic of pathogenic cryptococci having a thick capsule to quickly and accurately detect whether a sample has a cryptococcal infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of in vitro diagnosis, and in particular to a sample analyzer, method and computer-readable storage medium for detecting cryptococci in a sample. Background Art

[0002] Cryptococcus is a common fungus that can cause invasive infections in humans. The genus Cryptococcus includes 17 species and 18 variants, and the most pathogenic to humans is Cryptococcus neoformans. Cryptococcus neoformans is widely distributed in nature and can also be found on the human body surface, oral cavity and intestines.

[0003] Cryptococcus is generally an exogenous infection. It invades the human body through the respiratory tract and can invade all organs and tissues when it spreads from the lungs through the bloodstream. The most common site is the central nervous system. Neonatal cryptococcosis is common in people with low cellular immunity, such as those with AIDS, malignant tumors, diabetes, organ transplants, and patients using large doses of glucocorticoids. In the past 20 years, the incidence of cryptococcosis has been increasing. It has become one of the most common complications of AIDS abroad and the leading cause of death from AIDS. In immunosuppressed patients, the incidence of cryptococcal infection is about 5% to 10%, and in AIDS patients, the infection rate of cryptococcosis can be as high as 30%. According to statistics, about 1 million people are infected with cryptococcosis each year worldwide, and the mortality rate can be as high as 63%. In China, cryptococcosis has been classified as a Class B infectious disease, equivalent to viral hepatitis, and is a serious fungal disease facing humans.

[0004] Currently, the detection methods for Cryptococcus include ink negative staining method, culture identification method, antigen detection method, antibody detection method, nucleic acid detection method, etc.

[0005] The ink negative staining method for cerebrospinal fluid is currently the most commonly used method for detecting cryptococci in clinical practice. Pathogenic cryptococci have a wide and thick capsule outside the body, which has strong refractive index. When negatively stained with ink, the capsule wraps around the body so that it is not stained by the ink. Therefore, a thick blank band can be seen outside the round and transparent body, while normal cells, other pathogens and non-pathogenic cryptococci in the cerebrospinal fluid are stained black by the ink and cannot be observed under a microscope.

[0006] The culture identification method is to inoculate the specimen on Sabouraud medium. Pathogenic cryptococci can grow at both 25°C and 37°C, while non-pathogenic cryptococci do not grow at 37°C. After 2 to 5 days of culture, observe the morphological characteristics of the colonies and take the colonies for biochemical identification. Cryptococcus neoformans is positive for phenoloxidase test and urease test, and can assimilate glucose, galactose, sucrose, inositol and raffinose, but cannot ferment sugars and alcohols.

[0007] Antigen detection method is a method of detecting cryptococcal capsular polysaccharide-specific antigens in cerebrospinal fluid or plasma using immunological methods such as latex agglutination test, ELISA, polyclonal antibody and monoclonal antibody method. Among them, latex agglutination test (LAT) is the most commonly used. LAT is an indirect agglutination test, which uses polystyrene latex particles as carriers, combines soluble antibodies with polystyrene latex particles, and prepares sensitized latex particles, which then react with antigens in the sample to be tested, and multiple latex particles are cross-linked to form agglutination.

[0008] Antibody detection methods use radioimmunoassay and tube agglutination tests to detect cryptococcal antibodies in serum.

[0009] The nucleic acid detection method uses polymerase chain reaction (PCR) to detect the specific nucleic acid sequence of pathogenic cryptococci in the sample, generally the cryptococcal capsule-associated protein gene (CAP10).

[0010] The detection sensitivity of the ink negative staining method and the culture identification method is low, and the culture identification method takes a long time to culture. Although the antigen, antibody and nucleic acid detection methods have high sensitivity, their false positive rates are high, the detection costs are high, and these tests are not routine tests. Whether to conduct such tests needs to be judged based on the experience of clinicians. Therefore, subjective factors are also one of the reasons that restrict the development of such detection projects.

[0011] Therefore, it is necessary to develop a more convenient and accurate method for detecting Cryptococcus. Summary of the invention

[0012] The purpose of the present application is to provide a sample analyzer and method for detecting Cryptococcus conveniently, quickly and accurately.

[0013] To this end, the first aspect of the present application provides a sample analyzer, the sample analyzer comprising:

[0014] A sampling device, comprising a pipette with a pipette nozzle and a driving device for driving the pipette to quantitatively suck a sample to be tested through the pipette nozzle;

[0015] A sample preparation device, comprising at least one reaction pool and a reagent supply part, wherein the at least one reaction pool is used to receive the sample to be tested sucked by the sampling device, and the reagent supply part provides a hemolysis reagent and a fluorescent reagent to the at least one reaction pool, so that the sample to be tested sucked by the sampling device and the hemolysis reagent and the fluorescent reagent provided by the reagent supply part are mixed in the reaction pool to prepare a sample to be tested;

[0016] An optical detection device, comprising a light source, a flow chamber, at least one scattered light detector and a fluorescence detector, wherein the particles of the sample to be tested can pass through the flow chamber one by one, the light emitted by the light source illuminates the particles in the flow chamber to generate optical information, the at least one scattered light detector is used to collect at least one scattered light intensity information, and the fluorescence detector is used to collect fluorescence intensity information, wherein the optical information includes the at least one scattered light intensity information and the fluorescence intensity information; and

[0017] A control device is electrically connected to the optical detection device and includes a processor and a storage medium storing a computer program, wherein the control is configured to perform the following steps when the computer program is executed by the processor: obtaining at least two types of light intensity information in the optical information from the optical detection device, and distinguishing cryptococcal particle groups in the sample to be tested based on the at least two types of light intensity information.

[0018] A second aspect of the present application provides another sample analyzer, the sample analyzer comprising:

[0019] A sampling device, comprising a pipette with a pipette nozzle and a driving device for driving the pipette to quantitatively suck a sample to be tested through the pipette nozzle;

[0020] A sample preparation device, comprising at least one reaction pool and a reagent supply unit, wherein the at least one reaction pool is used to receive the sample to be tested sucked by the sampling device, and the reagent supply unit is configured to provide a hemolysis reagent to the at least one reaction pool, so that the sample to be tested sucked by the sampling device and the hemolysis reagent provided by the reagent supply unit are mixed in the at least one reaction pool to prepare a sample to be tested;

[0021] An optical detection device, comprising a light source, a flow chamber, a first scattered light detector and a second scattered light detector, wherein the particles of the sample to be tested can pass through the flow chamber one by one, the light emitted by the light source irradiates the particles in the flow chamber to generate optical information, the first scattered light detector is used to collect forward scattered light intensity information, and the second scattered light detector is used to collect side scattered light intensity information, wherein the optical information includes the forward scattered light intensity information and the side scattered light intensity information; and

[0022] A control device is electrically connected to the optical detection device and includes a processor and a storage medium storing a computer program, wherein the control is configured to perform the following steps when the computer program is executed by the processor: acquiring the optical information from the optical detection device, and distinguishing the cryptococcal particle group in the sample to be tested based on the optical information.

[0023] A third aspect of the present application provides a method for detecting cryptococci in a sample, the method comprising the following steps:

[0024] Processing the sample to be tested to obtain the sample to be tested, wherein the processing of the sample to be tested includes mixing the sample to be tested with a hemolysis reagent;

[0025] Allowing particles in the sample to be tested to pass through an optical detector one by one to obtain optical information of each particle in the sample to be tested;

[0026] The cryptococcal particle group in the sample to be tested is distinguished according to the optical information.

[0027] A fourth aspect of the present application provides another method for detecting cryptococci in a sample, the method comprising the following steps:

[0028] Processing a first portion of the sample to be tested to obtain a first sample to be tested, wherein the processing of the first portion of the sample to be tested includes mixing the first portion of the sample with a first hemolysis reagent and a first fluorescent dye;

[0029] Allowing particles in the first sample to be tested to pass through an optical detector one by one to obtain first optical information of each particle in the first sample to be tested;

[0030] Differentiate and count cryptococcal particles in the first test sample according to the first optical information to obtain a first cryptococcal particle count value;

[0031] Processing a second portion of the sample to be tested to obtain a second sample to be tested, wherein the processing of the second portion of the sample to be tested includes mixing the second portion of the sample with a second hemolysis reagent different from the first hemolysis reagent;

[0032] Allowing particles in the second sample to be tested to pass through the optical detector one by one to obtain second optical information of each particle in the second sample to be tested;

[0033] Differentiate and count cryptococcal particles in the second test sample according to the second optical information to obtain a second cryptococcal particle count value;

[0034] According to the first cryptococcal particle count value and the second cryptococcal particle count value, it is determined whether there is cryptococcal infection in the sample to be tested.

[0035] A fifth aspect of the present application provides a computer-readable storage medium, on which a computer program is stored, characterized in that when the computer program is executed by a processor, the various steps of the method described in the third and fourth aspects of the present application are implemented.

[0036] The present invention utilizes the characteristic of the pathogenic cryptococcus having a thick capsule and utilizes an instrument such as a fully automatic blood analyzer to quickly and accurately detect whether a sample has cryptococcal infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] In the drawings, the same reference numerals refer to the same or similar components.

[0038] Figure 1 A schematic diagram of the process of detecting cryptococcus according to the present invention;

[0039] Figure 2 A schematic diagram of a method for detecting cryptococci according to an embodiment of the present invention;

[0040] Figure 3 This is a schematic diagram of the principle of detecting cryptococcus according to the first embodiment of the present invention;

[0041] Figure 4 This is a schematic diagram of a method for detecting cryptococcus according to a first embodiment of the present invention;

[0042] Figure 5 A schematic diagram of a method for detecting cryptococci in cerebrospinal fluid samples according to a first embodiment;

[0043] Figure 6 Based on Figure 5 Optical scatter plots of cryptococcal negative and positive cerebrospinal fluid samples obtained by the indicated detection methods;

[0044] Figure 7 It is a schematic diagram of the process of detecting cryptococcus in a blood sample according to the first embodiment;

[0045] Figure 8 A schematic diagram of the principle of detecting cryptococcus according to a second embodiment of the present invention;

[0046] Fig. 9 This is a schematic diagram of a method for detecting cryptococcus according to a second embodiment of the present invention;

[0047] Fig.10 Based on Fig. 9 Optical detection scatter plots of cryptococcal negative and positive cerebrospinal fluid samples obtained by the indicated detection methods;

[0048] Fig.11 A schematic diagram of a method for detecting cryptococci in a blood sample according to a second embodiment;

[0049] Fig.12 A schematic diagram of another method for detecting cryptococcus according to the present invention;

[0050] Fig.13is a schematic structural diagram of a sample detector according to the present invention; and

[0051] Fig.14 Schematic diagram of the structure of an optical detection device according to the present invention. DETAILED DESCRIPTION

[0052] The technical solution of the present invention will be clearly and completely described below in conjunction with the specific embodiments of the present invention and the accompanying drawings. Obviously, the described embodiments are only part of the implementation methods of the present invention, not all of the implementation methods. Based on the implementation methods of the present invention, all other implementation methods obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0053] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0054] 'Cryptococcus' mentioned herein, unless otherwise specified, refers to Cryptococcus neoformans, the most common pathogenic species in the genus Cryptococcus.

[0055] The 'sample' mentioned herein, unless otherwise specified, refers to a body fluid sample or a blood sample, such as cerebrospinal fluid, pleural effusion, ascites, myocardial fluid, synovial fluid, peritoneal dialysis fluid, or fluid obtained from peritoneal lavage.

[0056] As used herein, 'hemolytic agent', unless otherwise specified, refers to an agent capable of lysing red blood cells while leaving white blood cells in their basic cell morphology.

[0057] The 'fluorescent dye' mentioned herein, unless otherwise specified, refers to a dye that can specifically bind to a nucleic acid substance (such as DNA, RNA) and emit fluorescence of a specific wavelength under excitation. There is no particular limitation on the nucleic acid-specific dye used in the present invention. Commercial nucleic acid fluorescent dyes and nucleic acid-specific fluorescent dyes disclosed in some patent applications can be used in the present invention. Among the commercial nucleic acid fluorescent dyes, the SYTO series nucleic acid dyes of Thermofisher can be cited. In addition, the fluorescent dyes disclosed in Chinese patent application CN201010022414.6, the anthocyanin dyes disclosed in CN200910109215.6, the fluorescent dyes disclosed in CN200810216864.1, etc. can all be used in the present invention. The entire contents of the above patent documents are incorporated into this application by reference.

[0058] The sample detection principle mentioned in this article refers to the fact that after the blood cell analyzer absorbs body fluid or blood samples, the samples are first treated with hemolytic agents and optionally fluorescent dyes. Red blood cells are destroyed and dissolved by the hemolytic agent, and other particles, such as white blood cells, cannot be dissolved. The fluorescent dye can enter other particles, such as the nucleus of white blood cells, with the help of the hemolytic agent, and bind to the nucleic acid substances in the nucleus. Then, the particles in the treated sample pass through the laser detection hole one by one. When the laser beam passes through the particles, the characteristics of the particles themselves (such as volume, staining degree, size and content of cell contents, cell nucleus density, etc.) can block or change the direction of the laser beam, and generate scattered light of various angles corresponding to its characteristics. After these scattered lights are received by the signal detector, relevant information about the structure and composition of the particles can be obtained. Among them, forward scattered light (FS) reflects the number and volume of particles, side scattered light (SS) reflects the complexity of the internal structure of particles (such as particles or nuclei in particles), and fluorescent signal (FL) reflects the content of nucleic acid substances in particles. These parameters can be used to classify and count particles in the sample.

[0059] The inventors have found that the hemolytic agent acting on the thick capsule of pathogenic cryptococci can produce optical properties different from other particles in the sample, so that the pathogenic cryptococci in the sample can be detected using the hemolytic channel of a conventional blood analyzer. In addition, the detection method of the present invention does not affect the normal detection of the hemolytic channel, so it can also detect the indicators in the sample that can be detected by the conventional hemolytic channel.

[0060] Therefore, the present application proposes a method for detecting cryptococci in a sample. Figure 1 , wherein a schematic flow chart of the method is shown. The method comprises the following steps:

[0061] Step S11, processing the sample to be tested to obtain the sample to be tested, wherein processing the sample to be tested includes at least processing the sample with a hemolysis reagent;

[0062] Step S12, allowing the particles in the sample to be tested to pass through an optical detector one by one to obtain optical information of each particle in the sample to be tested; and

[0063] In step S13, the cryptococcal particle group in the sample to be tested is distinguished according to the optical information.

[0064] The hemolytic reagent of the present invention may contain those hemolytic agents conventionally used for detecting blood cells. For example, the hemolytic agent that can be used in the present invention can be selected from surfactants (such as quaternary ammonium salt cationic surfactants, non-ionic surfactants, such as alkyl alcohol polyoxyethylene ether surfactants, etc.), alkyl glycosides, triterpenoid saponins, steroidal saponins, etc. The hemolytic reagent may also contain components such as buffers (such as phosphoric acid and its salts, citric acid and its salts, acetic acid and its salts, etc.), preservatives (such as sodium azide, ProClin series, etc.), metal chelators (such as sodium salt of EDTA), osmotic pressure regulators (such as sodium chloride, etc.).

[0065] The size range of cryptococcal bacteria is relatively wide, about 5 to 20 μm, which is reflected in the trend of the forward scattered light intensity extending from small to large, and part of it overlaps with the forward scattered light intensity of white blood cells. On the other hand, the complexity of the internal structure of cryptococcal bacteria is lower than that of white blood cells, so the side scattered light intensity of cryptococcus is slightly lower than that of white blood cells.

[0066] Therefore, in one embodiment, after the sample to be tested is treated with a hemolytic agent, the cryptococcal particle group in the sample to be tested can be distinguished according to the forward scattered light intensity information and the side scattered light intensity information in the optical information.

[0067] The cryptococcal particle group in the test sample may further be counted, and optionally, when the count value of the cryptococcal particle group exceeds a predetermined value, it indicates that cryptococcal infection exists in the test sample.

[0068] According to one embodiment, the sample to be tested may be further treated with a fluorescent dye reagent.

[0069] In this embodiment, the fluorescent dye reagent may contain a fluorescent dye capable of staining nucleic acid. The present invention has no particular limitation on the type of fluorescent dye, and any fluorescent dye defined above may be used as required.

[0070] The fluorescent dye reagent may also contain components such as a buffer, a surfactant, a preservative, a metal chelating agent, an osmotic pressure regulator, etc., which will not be described in detail here.

[0071] In a specific embodiment, the hemolytic reagent and the fluorescent dye reagent can be two separate reagents, which are mixed with the sample sequentially or simultaneously to prepare the test sample; or the hemolytic reagent and the fluorescent dye reagent can also be combined into a reagent containing both the hemolytic reagent and the fluorescent dye.

[0072] See also Figure 2 , which shows a schematic diagram of the process of this embodiment. Figure 2As shown, in this embodiment, first in step S110, the sample to be tested is mixed with a hemolytic reagent and a fluorescent dye reagent (or a reagent containing a hemolytic agent and a fluorescent dye), and the sample to be tested is obtained after the reaction. In step S120, the particles in the sample to be tested are passed through an optical detection device one by one to obtain optical information of each particle in the sample. And in step S130, based on the detected fluorescence intensity information and at least one scattered light intensity information, such as forward scattered light intensity information and / or side scattered light intensity information, the cryptococcal particles in the sample to be tested can be distinguished from other particles.

[0073] In step S130, the cryptococcal particle group in the sample to be tested is preferably distinguished based on the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information.

[0074] It can be understood that in step S130, the cryptococcal particle group in the sample to be tested can also be distinguished according to the forward scattered light intensity information and the side scattered light intensity information in the optical information.

[0075] Furthermore, the cryptococcal particle group in the test sample may be counted, and optionally, when the count value of the cryptococcal particle group exceeds a predetermined value, it indicates that cryptococcal infection exists in the test sample.

[0076] According to a specific situation, the sample to be tested is a body fluid sample, especially a cerebrospinal fluid sample. In this case, the body fluid sample to be tested can be treated with a hemolytic reagent, and after optical detection, the cryptococcal particle group in the sample can be distinguished according to the forward and side scattered light intensity information. Alternatively, the body fluid sample to be tested can be treated with a hemolytic reagent and a fluorescent dye reagent, and after optical detection, the cryptococcal particle group in the sample can be distinguished according to at least one scattered light intensity information (forward scattered light intensity information and / or side scattered light intensity information) and fluorescence intensity information.

[0077] In the case where the sample to be tested is a body fluid sample, at least one of the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group, and the multinuclear cell particle group can be further distinguished according to specific needs based on the side scattered light intensity information and the fluorescence intensity information in the optical information, preferably based on the forward scattered light intensity information, the side scattered light intensity information, and the fluorescence intensity information in the optical information. Furthermore, at least one of the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group, and the multinuclear cell particle group can be counted.

[0078] According to another specific situation, the sample to be tested may be a blood sample. Similarly, in this case, the blood sample can be processed with a hemolytic reagent to obtain a sample to be tested, and then the sample to be tested is optically detected to obtain optical information including forward scattered light intensity information and side scattered light intensity information, and then the cryptococcal particle group is distinguished by the obtained optical information. In addition, the white blood cell subpopulations including lymphocytes, monocytes, neutrophils and eosinophils in the sample can also be distinguished by the obtained optical information, that is, according to the forward scattered light intensity information and the side scattered light intensity information. And the cryptococcal particle group and the distinguished white blood cell subpopulations can be further counted, and optionally, when the count value of the cryptococcal particle group exceeds a predetermined value, it indicates that there is a cryptococcal infection in the sample to be tested.

[0079] According to another embodiment, when the sample to be tested is a blood sample, the blood sample can be processed with a hemolytic reagent and a fluorescent dye reagent (or with a reagent containing a hemolytic agent and a fluorescent dye) to obtain a sample to be tested. In this embodiment, the sample to be tested is optically detected to obtain optical information including fluorescence intensity information and at least one scattered light intensity information. In some embodiments, on the one hand, the cryptococcal particle group is distinguished by the obtained optical information (e.g., using one or two scattered light intensity information and fluorescence intensity information); on the other hand, the leukocyte subpopulation including lymphocytes, monocytes, neutrophils and eosinophils and / or the immature granulocyte group can be distinguished based on the side scattered light intensity information and the fluorescence intensity information in the optical information, preferably based on the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, and the leukocyte subpopulation and / or the immature granulocyte group can be distinguished, and the distinguished leukocyte subpopulation and / or the immature granulocyte group can be further selected to be counted. In other embodiments, on the one hand, cryptococcal particle groups are distinguished by the obtained optical information; on the other hand, the nucleated red blood cell particle group and at least one particle group of the basophil subpopulation in the sample to be tested can be distinguished according to the forward scattered light intensity information and the fluorescence intensity information in the optical information, preferably according to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information. And at least one particle group of the distinguished nucleated red blood cell particle group and the basophil subpopulation can be further selected to be counted.

[0080] Furthermore, distinguishing the cryptococcal particle group in the sample to be tested according to the optical information includes:

[0081] generating a two-dimensional or three-dimensional scatter plot according to the optical information;

[0082] Obtaining a cryptococcal particle characteristic region according to the two-dimensional or three-dimensional scatter plot; and

[0083] The particles in the cryptococcal particle characteristic region are identified as cryptococcal particles.

[0084] Based on the characteristic that pathogenic Cryptococcus neoformans has a wide and thick capsule outside the thalli, the inventors further discovered that red blood cell hemolytic agents with different pH values ​​can produce different effects on the capsule of cryptococcus. Under neutral conditions, such as pH 6.5-7.5, the hemolytic agent will basically not damage the capsule of cryptococcus, that is, the wide and thick capsule outside the cryptococcus thalli can prevent the "perforation effect" of the neutral hemolytic agent to a certain extent, and then prevent the fluorescent dye from entering the cryptococcal body to a certain extent. Under this pH condition, the hemolytic agent can rupture the cell membrane of red blood cells, and the cell membrane of white blood cells will also be damaged to a certain extent, causing a "perforation effect". The fluorescent dye enters the cell through the pores on the cell membrane of the white blood cells and combines with the nucleic acid substance in the white blood cells. Under acidic conditions, such as pH 2-4, the hemolytic agent will also cause certain damage to the capsule of cryptococcus, producing a "perforation effect" similar to that of the cell membrane of white blood cells, so that the fluorescent dye can enter the cryptococcal body.

[0085] Therefore, according to a more specific embodiment, the hemolysis reagent may have a pH value of about 2.0 to 4.0, preferably a pH value of about 3.0; or the hemolysis reagent may have a pH value of about 6.5 to 7.5, preferably a pH value of about 7.0. The specific embodiments at different pH values ​​are described below.

[0086] According to the first embodiment, the sample is treated with a hemolytic reagent and further with a fluorescent dye reagent to obtain a test sample. In this embodiment, the hemolytic reagent may have a pH value of about 6.5 to 7.5, preferably a pH value of about 7.0. In the test sample, the red blood cells are broken under the action of the hemolytic agent; the cell membrane of the white blood cells is punctured, and the fluorescent dye enters the interior of the white blood cells through the holes in the cell membrane, so that the nuclear material therein is stained; while the capsule of the cryptococcus remains basically intact, and the nuclear material in the bacterial body is basically not stained, such as Figure 3 shown.

[0087] like Figure 4 As shown, in this embodiment, first in step S111, the sample is mixed with a hemolysis reagent and a fluorescent dye reagent, and reacted to obtain a sample to be tested. Similarly, when processing the sample, the hemolysis reagent and the fluorescent dye reagent can be added successively, or they can be added simultaneously. The hemolysis reagent and the fluorescent dye reagent can exist separately in different reagents, or they can exist in the same reagent. In addition, other necessary processing can be performed on the sample, for example, in some embodiments, the sample can be diluted.

[0088] In step S112, the particles in the sample to be tested are passed through an optical detection device one by one to obtain optical information of each particle in the sample.

[0089] In this embodiment, since the nuclear material in the cryptococcal body can basically not be stained by fluorescent dyes, it shows an extremely low fluorescence intensity signal, while nucleated cells such as white blood cells are stained and show a certain fluorescence intensity. On the other hand, the complexity of the internal structure of the cryptococcal body is lower than that of white blood cells, so the side scattered light intensity of the cryptococcus is slightly lower than that of white blood cells. On the other hand, the size range of the cryptococcal body is relatively wide, about 5 to 20 μm, which is reflected in the trend of the forward scattered light intensity extending from small to large, part of which overlaps with the forward scattered light intensity of white blood cells, and the maximum forward scattered light intensity of the cryptococcal particles is greater than the maximum forward scattered light intensity of the white blood cell particles. Therefore, in step S113, the cryptococcal particles can be distinguished from other particles in the sample based on the detected fluorescence intensity and forward scattered light intensity, especially based on the fluorescence intensity, forward scattered light intensity and side scattered light intensity.

[0090] Then, in step S114, the differentiated cryptococcal particle groups are counted, and in step S115, the count value is compared with a predetermined value, so as to know whether the tested sample is infected with cryptococcus.

[0091] In this embodiment, information about other particles in the sample can be further obtained.

[0092] For example, see Figure 5 , which shows the detection steps for body fluid samples, especially cerebrospinal fluid samples, when using a neutral hemolytic agent. Figure 4 Description of step S111 and step S112 shown. After obtaining the optical information of each particle in the sample, on the one hand, in step S1113, the cryptococcal particle group can be distinguished according to the optical information (specifically, it can be forward scattered light intensity information and fluorescence intensity information, or it can be forward scattered light intensity information, side scattered light intensity information and fluorescence intensity information); and the cryptococcal particle group can be further counted in step S1114; and then, in step S1115, the counting result is compared with a predetermined value, and when the count value exceeds the predetermined value, it can be determined that there is cryptococcal infection in the cerebrospinal fluid sample. On the other hand, in step S1116, at least one particle group among the white blood cell particle group, nucleated cell particle group, mononucleated cell particle group, and polynucleated cell particle group can be further distinguished according to the side scattered light intensity information and fluorescence intensity information in the measured optical information, especially the forward scattered light intensity information, the side scattered light intensity information, and the fluorescence intensity information as needed; and at least one particle group can be further counted in step S1117.

[0093] See also Figure 6, which shows a scatter plot formed by optical information after two cerebrospinal fluid samples were tested using the BC-6800 blood cell analyzer of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and its DIFF channel supporting 68-LD hemolysis reagent and corresponding fluorescent dye, the supporting 68-LD hemolysis reagent has a pH value of about 7.0. Among them, in the scatter plot of the cerebrospinal fluid sample with positive cryptococcus, the three-dimensional scatter plot and the two-dimensional scatter plot of fluorescence-forward scattered light intensity can distinguish cryptococcus from other particles (the circled range is the optical information of the corresponding cryptococcus), while the optical information of cryptococcal particles is not detected at the corresponding position in the scatter plot of the cerebrospinal fluid sample with negative cryptococcus.

[0094] See also Figure 7 , which shows the specific detection steps for blood samples when using a neutral hemolytic agent. Figure 7 Steps S1121 and S1122 in the above Figure 4 Steps S111 and S112 in are basically the same. Figure 7 In the example shown, the blood sample is processed and tested using a reagent containing a hemolytic agent and a fluorescent dye in a conventional blood analyzer (e.g., the reagents for the DIFF channel of the BC-6800 blood cell analyzer produced by Shenzhen Mindray Bio-Medical Electronics Co., Ltd.). Steps S1123, S1124, and S1125 are respectively Figure 4 In the example shown, step S113 is the same as steps S114 and S115. In step S1126, the conventional DIFF channel detection step for white blood cells is performed, that is, the white blood cell particle group can be distinguished according to the obtained optical information, and the white blood cell subpopulation can be further distinguished. Specifically, according to the side scattered light intensity information and the fluorescence intensity information in the measured optical information, preferably according to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, the white blood cell subpopulations including lymphocytes, monocytes, neutrophils and eosinophils and / or the immature granulocyte group can be distinguished. Further, in step S1127, the distinguished white blood cell subpopulations and / or immature granulocyte group can be counted.

[0095] According to a second embodiment, the sample is treated with a hemolytic reagent to obtain a test sample. In this embodiment, the hemolytic reagent may have a pH value of about 2.0 to 4.0, preferably a pH value of about 3.0. In the test sample, the red blood cells are broken under the action of the acidic hemolytic agent; the cell membrane of the white blood cells is perforated, and at the same time, the capsule of the cryptococcus is also damaged to a certain extent, thereby forming a perforation phenomenon on its cell membrane similar to that of the white blood cells. If the sample is further stained with a fluorescent staining reagent, the dye will enter the interior of the white blood cells through the holes in the cell membrane, and also enter the interior of the cryptococcal body, so that both the white blood cells and the nuclear material of the cryptococcus are stained, such as Figure 8 shown.

[0096] In this embodiment, see Fig. 9 In step S121, the red blood cells in the sample are broken under the action of the acidic hemolytic agent, while the white blood cells and cryptococci are both affected by the hemolytic agent and due to the differences in their respective volumes and complexity, they show obvious differences in scattered light intensity, so that cryptococci can be distinguished from other particles such as white blood cells. If the sample is further stained with a fluorescent staining reagent, the nucleic acid substances of white blood cells and cryptococci can be stained. In step S122, the particles in the sample are passed through an optical detection device one by one to obtain optical information of each particle in the sample to be tested. In step S123, the cryptococcal particle group is distinguished according to the optical information. Among them, in the case of not being treated with a fluorescent staining reagent, the cryptococcal particle group can be distinguished according to the forward scattered light intensity information and the side scattered light intensity information. When the fluorescent staining reagent is used for treatment, the cryptococcal particles can be distinguished from other particles such as white blood cells according to the forward scattered light intensity information and the side scattered light intensity information, especially according to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information. In steps S124 and S125, by counting the differentiated cryptococcal particle groups and comparing them with a predetermined value, it can be determined whether the sample being tested is infected with cryptococcus.

[0097] In this embodiment, the sample may not be treated with a fluorescent dye, but only with a hemolysis reagent. Similarly, if a hemolysis reagent and a fluorescent dye reagent are needed for treatment, the two may be added successively or simultaneously. The sample may also be further treated with other methods.

[0098] See also Fig.10 , wherein a scatter plot of two different cerebrospinal fluid samples after detection using the 68-LN hemolysis reagent and corresponding fluorescent dyes of the BC-6800 blood cell analyzer and its WNB channel of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is shown, and the 68-LN hemolysis reagent has a pH value of about 3.0. In the scatter plot of the cerebrospinal fluid sample with positive cryptococcus, the three-dimensional scatter plot and the two-dimensional scatter plot of forward scattered light intensity-side scattered light intensity can distinguish cryptococcus from other particles (the circled range is the optical information of the corresponding cryptococcus). In the three-dimensional scatter plot of the cerebrospinal fluid sample with negative cryptococcus and the two-dimensional scatter plot of forward scattered light intensity-side scattered light intensity, no optical information of cryptococcal particles was detected at the corresponding positions.

[0099] See also Fig.11, which shows a specific implementation method using blood as a sample in this implementation method. This implementation method uses a conventional blood analyzer (such as the BC-6800 series blood cell analyzer of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and its WNB channel supporting reagents) to perform detection in the WNB channel. In step S1221, under acidic conditions, the blood sample is treated with a hemolysis reagent and a fluorescent dye reagent to obtain a sample to be tested, and further in step S1222, the sample is passed through an optical detection device to obtain optical information of each particle in the sample, that is, scattered light intensity information and fluorescence intensity information.

[0100] Then in steps S1223 to S1225, cryptococcal particle groups are distinguished according to the forward scattered light intensity information and the side scattered light intensity information in the optical information, especially according to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information, and the cryptococcal particle groups can be further counted, and then the count value of the cryptococcal particle group is compared with a predetermined value to determine whether cryptococcal infection exists in the sample.

[0101] Furthermore, in steps S1226 to S1227, the nucleated red blood cell particle group and / or basophil subpopulation can be distinguished based on the forward scattered light intensity information and the fluorescence intensity information in the optical information, especially based on the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, and the nucleated red blood cell particle group and / or the basophil subpopulation can be further counted.

[0102] The present invention also provides another method for detecting cryptococci in a sample, wherein two parts of the sample to be tested are treated separately with hemolytic agents that have different effects on the capsule of cryptococci to obtain a first count and a second count of cryptococci in the sample to be tested, and whether cryptococcal infection exists in the sample to be tested is determined based on the first count and the second count.

[0103] Specifically, see Fig.12 In step S1310, the sample to be tested (body fluid sample or blood sample) is divided into a first sample and a second sample. Then, different hemolysis reagents are used to process the first sample and the second sample.

[0104] In steps S1311 to S1314, the first portion of the sample is processed with a first hemolysis reagent and a first fluorescent dye reagent to obtain a first sample to be tested, and the first optical information of the first sample to be tested is obtained by an optical detection device. Then, the cryptococcal particle group in the first sample to be tested is distinguished according to the first optical information, and the cryptococcal particle group in the first sample to be tested is counted to obtain a first count value.

[0105] In some embodiments, the first optical information includes forward scattered light intensity information and fluorescence scattered light intensity information, preferably includes forward scattered light intensity information, side scattered light intensity information and fluorescence intensity information.

[0106] In some embodiments, the first hemolysis reagent has a pH value of about 6.5 to 7.5, preferably about 7.0.

[0107] At the same time or successively, in steps S1321 to S1324, a second portion of the sample is treated with a second hemolytic reagent different from the first hemolytic reagent to obtain a second sample to be tested, and the second optical information of the second sample to be tested is obtained by the optical detection device. The cryptococcal particle group of the second sample to be tested is distinguished according to the second optical information, and the cryptococcal particle group in the second sample to be tested is counted to obtain a second count value.

[0108] In some embodiments, the second optical information includes forward scattered light intensity information and side scattered light intensity information.

[0109] In some embodiments, step S1321 includes: mixing the second portion of the sample with a second hemolysis reagent different from the first hemolysis reagent and a second fluorescent reagent different from the first fluorescent reagent. The second optical information includes forward scattered light intensity information, side scattered light intensity information and fluorescence intensity information.

[0110] In some embodiments, the second hemolysis reagent has a pH value of about 2.0 to 4.0, preferably about 3.0.

[0111] In step 1330, it is determined whether there is cryptococcal infection in the sample to be tested according to the first count value and the second count value. For example, when the first count value exceeds the first preset value, the second count value exceeds the second preset value, and the difference between the first count value and the second count value is within a preset range, it is determined that there is cryptococcal infection in the sample to be tested.

[0112] In a specific embodiment, for example, two detection channels of a sample analyzer (such as the DIFF channel and its supporting reagents and the WNB channel and its supporting reagents of the BC-6800 series hematology analyzer of Shenzhen Mindray Bio-Medical Electronics Co., Ltd.) are used to simultaneously detect the first part of the sample and the second part of the sample to be tested to obtain a first cryptococcal count value and a second cryptococcal count value.

[0113] Accordingly, the present application further provides a sample analyzer capable of detecting Cryptococcus.

[0114] See also Fig.13The sample analyzer includes: a first housing 100, a second housing 200, a sampling device 10, a sample preparation device 30, an optical detection device 50, a control device 70 and an output unit 90. In practical applications, the output unit 90 can be a user interface. The optical detection device 50 and the data processing device 70 are arranged inside the second housing 200, for example, they can be arranged on both sides of the second housing 200 respectively. The sample preparation device 30 is, for example, arranged inside the first housing 100, and the output unit 90 is, for example, arranged on the outer surface of the first housing 100 and is used to display the detection result of the sample analyzer, for example, display the detection result of Cryptococcus to the user.

[0115] The sampling device 10 has a pipette with a pipette nozzle and a driving device, which is used to drive the pipette to quantitatively absorb the sample to be tested through the pipette nozzle. The sampling device can transport the collected blood sample to the sample preparation device 30. According to different embodiments, the sampling device can collect multiple blood samples, provide them to different chambers of the sample preparation device for different processing, and then perform different tests. The sampling device can be used to absorb body fluid samples or blood samples.

[0116] The sample preparation device 30 has at least one reaction pool and a reagent supply unit, wherein the at least one reaction pool is used to receive the sample to be tested sucked by the sampling device, and the reagent supply unit provides a hemolysis reagent and a fluorescent reagent to the at least one reaction pool, so that the sample to be tested sucked by the sampling device and the hemolysis reagent and fluorescent reagent provided by the reagent supply unit are mixed in the reaction pool to prepare the sample to be tested.

[0117] The optical detection device 50 includes a light source, a flow chamber, at least one scattered light detector and a fluorescence detector. The particles of the sample to be tested can flow in the flow chamber. The light emitted by the light source illuminates the particles in the flow chamber to generate optical information. The at least one scattered light detector is used to collect at least one scattered light intensity information, and the fluorescence detector is used to collect fluorescence intensity information, wherein the optical information includes the at least one scattered light intensity information and the fluorescence intensity information.

[0118] like Fig.14As shown, a specific example of an optical detection device 50 is shown. The optical detection device has a light source 101, a beam shaping component 102, a flow chamber 103, and a forward scattered light detector 104, which are arranged in a straight line in sequence. A dichroic mirror 106 is arranged at a 45° angle to the straight line on one side of the flow chamber 103. A part of the side light emitted by the particles in the flow chamber 103 passes through the dichroic mirror 106 and is captured by a fluorescence detector 105 arranged at a 45° angle behind the dichroic mirror 106; another part of the side light is reflected by the dichroic mirror 106 and is captured by a side scattered light detector 107 arranged at a 45° angle to the dichroic mirror 106.

[0119] The control device 70 is electrically connected to the optical detection device and includes a processor and a storage medium storing a computer program, wherein the control device is configured to perform the following steps when the computer program is executed by the processor: obtaining at least two types of light intensity information in the optical information from the optical detection device, and distinguishing the cryptococcal particle group in the sample to be tested based on the at least two types of light intensity information.

[0120] The output unit 90 is configured to output the detection result of Cryptococcus in the sample, and optionally the detection result of other particles.

[0121] Among them, the sample, hemolysis reagent and fluorescent staining reagent are as described above and will not be repeated here.

[0122] In some embodiments, the at least one scattered light detector includes a forward scattered light detector for collecting forward scattered light intensity information, and optionally includes a side scattered light detector for collecting side scattered light intensity information. Wherein, the control device 70 is configured to perform the following steps when the computer program is executed by the processor:

[0123] The cryptococcal particle group in the sample to be tested is distinguished according to the forward scattered light intensity information and the fluorescence intensity information in the optical information, preferably according to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information.

[0124] In some embodiments, when the sample to be tested is a cerebrospinal fluid sample, the control device 70 is configured to further perform the following steps when the computer program is executed by the processor:

[0125] According to the side scattered light intensity information and the fluorescence intensity information in the optical information of the sample to be tested, preferably according to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, at least one particle group among the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group and the multi-nuclear cell particle group is distinguished, and at least one particle group is optionally counted.

[0126] In some embodiments, when the sample to be tested is a blood sample, the control device is configured to further perform the following steps when the computer program is executed by the processor:

[0127] According to the side scattered light intensity information and the fluorescence intensity information in the optical information or according to the forward scattered light intensity information and the side scattered light intensity information in the optical information, preferably according to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, distinguish the leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils and / or distinguish the immature granulocyte population in the sample to be tested, and optionally count the distinguished leukocyte subpopulations and / or immature granulocyte population, or

[0128] Based on the forward scattered light intensity information and the fluorescence intensity information in the optical information, preferably based on the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, the nucleated red blood cell particle group and at least one particle group of the basophil subpopulation in the sample to be tested are distinguished, and the at least one particle group is optionally counted.

[0129] Further, the control device may be configured to perform the following steps when distinguishing the cryptococcal particle group in the sample to be tested according to the at least two types of light intensity information:

[0130] generating a two-dimensional or three-dimensional scatter plot according to the at least two types of light intensity information;

[0131] Obtaining a cryptococcal particle characteristic region according to the two-dimensional or three-dimensional scatter plot; and

[0132] The particles in the cryptococcal particle characteristic region are identified as cryptococcal particles.

[0133] The control device is configured to further perform the following steps when the computer program is executed by the processor:

[0134] Counting the cryptococcal particles in the sample to be tested; and

[0135] Optionally, when the count value of the cryptococcal particle group exceeds a predetermined value, it indicates that cryptococcal infection exists in the sample to be tested.

[0136] The present application also provides another sample analyzer, the sample analyzer and Fig.13 The analyzer shown has a substantially identical structure, and also includes the aforementioned first housing, second housing, sampling device, sample preparation device, optical detection device, control device, and output unit.

[0137] The difference is that the sample preparation device of the sample analyzer has at least one reaction pool and a reagent supply unit, wherein the at least one reaction pool is used to receive the sample to be tested sucked by the sampling device, and the reagent supply unit can provide a hemolysis reagent to the at least one reaction pool, so that the sample to be tested sucked by the sampling device and the hemolysis reagent provided by the reagent supply unit are mixed in the reaction pool to prepare the sample to be tested.

[0138] Or, alternatively, the reagent supply section of the sample preparation device may provide the hemolysis reagent and the fluorescent dye reagent to the at least one reaction pool, so that the sample to be tested drawn by the sampling device is mixed with the hemolysis reagent and the fluorescent dye reagent provided by the reagent supply section in the reaction pool to prepare the sample to be tested.

[0139] In some embodiments, the optical detection device includes a light source, a flow chamber, a first scattered light detector and a second scattered light detector, and preferably also includes a fluorescence detector. The particles of the sample to be tested can flow in the flow chamber, the light emitted by the light source irradiates the particles in the flow chamber to generate optical information, the first scattered light detector is used to collect forward scattered light intensity information, and the second scattered light detector is used to collect side scattered light intensity information, wherein the optical information includes the forward scattered light intensity information and the side scattered light intensity information, and preferably, when a fluorescence detector is included, the fluorescence detector is used to collect fluorescence intensity information, and the optical information includes forward scattered light intensity information, side scattered intensity information and fluorescence intensity information.

[0140] Similarly, the control device is electrically connected to the optical detection device and includes a processor and a storage medium storing a computer program, wherein the control is configured to perform the following steps when the computer program is executed by the processor: acquiring the optical information from the optical detection device, and distinguishing the cryptococcal particle group in the sample to be tested based on the optical information.

[0141] In some embodiments, the sample preparation device includes a first reaction pool and a second reaction pool, and the reagent supply unit of the sample preparation device provides a first hemolysis reagent and a first fluorescent dye to the first reaction pool, so that the sample to be tested drawn by the sampling device is mixed with the first hemolysis reagent and the first fluorescent dye provided by the reagent supply unit in the first reaction pool to prepare a first sample to be tested, and the reagent supply unit also provides a second hemolysis reagent to the second reaction pool, so that the sample to be tested drawn by the sampling device is mixed with the second hemolysis reagent provided by the reagent supply unit in the second reaction pool to prepare a second sample to be tested. That is, the control device is configured to perform the following steps when the computer program is executed by the processor:

[0142] Controlling the sample preparation device to prepare a first sample to be tested by mixing a first portion of the sample to be tested with a first hemolysis reagent and a first fluorescent reagent to obtain the first sample to be tested;

[0143] Controlling the optical detection device to detect the first sample to be tested to obtain first optical information of each particle in the first sample to be tested;

[0144] Differentiate and count cryptococcal particles in the first test sample according to at least two types of light intensity information in the first optical information to obtain a first cryptococcal particle count value;

[0145] Controlling the sample preparation device to prepare a second sample to be tested by mixing a second portion of the sample to be tested with a second hemolysis reagent different from the first hemolysis reagent to obtain the second sample to be tested;

[0146] Controlling the optical detection device to detect the second sample to be tested to obtain second optical information of each particle in the second sample to be tested;

[0147] Differentiate and count cryptococcal particles in the second test sample according to at least two types of light intensity information in the second optical information to obtain a second cryptococcal particle count value;

[0148] According to the first cryptococcal particle count value and the second cryptococcal particle count value, it is determined whether there is cryptococcal infection in the sample to be tested.

[0149] In some embodiments, the first optical information includes forward scattered light intensity information and fluorescence intensity information, preferably includes forward scattered light intensity information, side scattered light intensity information and fluorescence intensity information.

[0150] In some embodiments, the second optical information includes forward scattered light intensity information and side scattered light intensity information.

[0151] In some embodiments, the control device is configured to perform the following steps when controlling the sample preparation device to prepare the second sample to be tested:

[0152] Controlling the sample preparation device to prepare a second sample to be tested by mixing a second portion of the sample to be tested with a second hemolytic reagent different from the first hemolytic reagent and a second fluorescent reagent different from the first fluorescent reagent to obtain the second sample to be tested;

[0153] The second optical information includes forward scattered light intensity information, side scattered light intensity information and fluorescence intensity information.

[0154] In some embodiments, the control device is configured to perform the following steps when determining whether there is cryptococcal infection in the sample to be tested:

[0155] When the difference between the first cryptococcal particle count value and the second cryptococcal particle count value is within a preset range, it is determined that cryptococcal infection exists in the sample to be tested.

[0156] The present application also provides a computer-readable storage medium, on which a computer program is stored, characterized in that the computer program implements each step of the aforementioned method when executed by a processor.

[0157] The computer-readable storage medium may be a volatile memory or a nonvolatile memory, or may include both volatile and nonvolatile memories. Among them, the nonvolatile memory may be a read-only memory, a programmable read-only memory, an erasable programmable read-only memory, an electrically erasable programmable read-only memory, a magnetic random access memory, a flash memory, a magnetic surface memory, an optical disk, or a read-only optical disk; the magnetic surface memory may be a disk memory or a tape memory. The volatile memory may be a random access memory, which is used as an external cache. By way of example but not limitation, many forms of RAM are available, such as static random access memory, synchronous static random access memory, dynamic random access memory, synchronous dynamic random access memory, double data rate synchronous dynamic random access memory, enhanced synchronous dynamic random access memory, synchronously connected dynamic random access memory, and direct memory bus random access memory. The memory described in the embodiments of the present invention is intended to include these and any other suitable types of memory.

[0158] The above-mentioned features can be combined with each other as desired, as long as they are meaningful within the scope of the present invention. The advantages and features described for each aspect of the method apply in a corresponding manner to the corresponding sample analyzer and the corresponding computer-readable storage medium, and vice versa.

[0159] The above description is only a preferred embodiment of the present invention, and does not limit the patent scope of the present invention. All equivalent structural changes made by using the contents of the present invention specification and drawings under the inventive concept of the present invention, or directly / indirectly applied in other related technical fields are included in the patent protection scope of the present invention.

Claims

1. A sample analyzer, comprising: A sampling device, comprising a pipette with a pipette nozzle and a driving device for driving the pipette to quantitatively suck a sample to be tested through the pipette nozzle; A sample preparation device, comprising at least one reaction pool and a reagent supply part, wherein the at least one reaction pool is used to receive the sample to be tested sucked by the sampling device, and the reagent supply part provides a hemolysis reagent and a fluorescent reagent to the at least one reaction pool, so that the sample to be tested sucked by the sampling device and the hemolysis reagent and the fluorescent reagent provided by the reagent supply part are mixed in the reaction pool to prepare a sample to be tested; An optical detection device, comprising a light source, a flow chamber, at least one scattered light detector and a fluorescence detector, wherein the particles of the sample to be tested can pass through the flow chamber one by one, the light emitted by the light source illuminates the particles in the flow chamber to generate optical information, the at least one scattered light detector is used to collect at least one scattered light intensity information, and the fluorescence detector is used to collect fluorescence intensity information, wherein the optical information includes the at least one scattered light intensity information and the fluorescence intensity information; and A control device electrically connected to the optical detection device and comprising a processor and a storage medium storing a computer program, wherein the control is configured to perform the following steps when the computer program is executed by the processor: Acquire at least two types of light intensity information in the optical information from the optical detection device; and generating a two-dimensional or three-dimensional scatter plot according to the at least two types of light intensity information, obtaining a cryptococcal particle characteristic region according to the two-dimensional or three-dimensional scatter plot, and identifying particles in the cryptococcal particle characteristic region as cryptococcal particles, Wherein, the at least two types of light intensity information include forward scattered light intensity information, and Wherein, in the two-dimensional or three-dimensional scatter plot, the forward scattered light intensity of the cryptococcal particles shows a trend extending from small to large.

2. The sample analyzer according to claim 1, wherein: In the test sample, the capsule of the cryptococcus is destroyed, and the inner core of the bacterial body is stained by the fluorescent reagent. The at least one light intensity information further includes side scattered light intensity information, and the control is configured to perform the following steps when the computer program is executed by the processor: A two-dimensional or three-dimensional scatter plot is generated based on at least two types of light intensity information including the forward scattered light intensity information and the side scattered light intensity information, a cryptococcal particle characteristic region is obtained based on the two-dimensional or three-dimensional scatter plot, and particles in the cryptococcal particle characteristic region are identified as cryptococcal particles.

3. The sample analyzer according to claim 1, wherein: In the test sample, the capsule of the cryptococcus remains basically intact, and the inner core material of the bacterial body cannot be stained by the fluorescent reagent. The at least one light intensity information further includes fluorescence intensity information, and the control is configured to perform the following steps when the computer program is executed by the processor: A two-dimensional or three-dimensional scatter plot is generated based on at least two types of light intensity information including the forward scattered light intensity information and the fluorescence intensity information, a cryptococcal particle characteristic region is obtained based on the two-dimensional or three-dimensional scatter plot, and particles in the cryptococcal particle characteristic region are identified as cryptococcal particles.

4. The sample analyzer according to any one of claims 1 to 3, wherein: The sampling device is configured to draw a body fluid sample or a blood sample.

5. The sample analyzer according to claim 1 or 2, wherein: The at least one scattered light detector comprises a forward scattered light detector for collecting forward scattered light intensity information; Wherein, the control device is configured to perform the following steps when the computer program is executed by the processor: The cryptococcal particle group in the sample to be tested is distinguished according to the forward scattered light intensity information and the fluorescence intensity information in the optical information.

6. The sample analyzer according to any one of claims 1 to 3, wherein: The at least one scattered light detector comprises a forward scattered light detector for collecting forward scattered light intensity information and a side scattered light detector for collecting side scattered light intensity information; Wherein, the control device is configured to perform the following steps when the computer program is executed by the processor: According to the forward scattered light intensity information and the fluorescence intensity information in the optical information, or according to the forward scattered light intensity information and the side scattered light intensity information in the optical information, or according to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, the cryptococcal particle group in the sample to be tested is distinguished.

7. The sample analyzer according to claim 6, wherein: The sample to be tested is a body fluid sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: At least one particle group among the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group, and the multinuclear cell particle group is distinguished according to the side scattered light intensity information and the fluorescence intensity information in the optical information.

8. The sample analyzer according to claim 6, wherein: The sample to be tested is a body fluid sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: According to the side scattered light intensity information and the fluorescence intensity information in the optical information, at least one particle group among the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group, and the multinuclear cell particle group is distinguished and the at least one particle group is counted.

9. The sample analyzer according to claim 6, wherein: The sample to be tested is a body fluid sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: At least one particle group among the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group, and the multinuclear cell particle group is distinguished according to the forward scattered light intensity information, the side scattered light intensity information, and the fluorescence intensity information in the optical information.

10. The sample analyzer according to claim 6, wherein: The sample to be tested is a body fluid sample; The control device is configured to further perform the following steps when the computer program is executed by the processor: According to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, at least one particle group among the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group and the multinuclear cell particle group is distinguished and the at least one particle group is counted.

11. The sample analyzer according to claim 6, wherein: The sample to be tested is a blood sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: According to the side scattered light intensity information and the fluorescence intensity information in the optical information or according to the forward scattered light intensity information and the side scattered light intensity information in the optical information, the leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils and / or the immature granulocyte population in the sample to be tested are distinguished.

12. The sample analyzer according to claim 6, wherein: The sample to be tested is a blood sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: According to the side scattered light intensity information and the fluorescence intensity information in the optical information or according to the forward scattered light intensity information and the side scattered light intensity information in the optical information, the leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils and / or the immature granulocyte population in the sample to be tested are distinguished, and the distinguished leukocyte subpopulations and / or the immature granulocyte population are counted.

13. The sample analyzer according to claim 6, wherein: The sample to be tested is a blood sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: According to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, the leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils and / or the immature granulocyte population in the sample to be tested are distinguished.

14. The sample analyzer according to claim 6, wherein: The sample to be tested is a blood sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: According to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, the leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils and / or the immature granulocyte population in the sample to be tested are distinguished, and the distinguished leukocyte subpopulations and / or the immature granulocyte population are counted.

15. The sample analyzer according to claim 5, wherein: The sample to be tested is a blood sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: According to the forward scattered light intensity information and the fluorescence intensity information in the optical information, at least one particle group of the nucleated red blood cell particle group and the basophil subgroup in the sample to be tested is distinguished.

16. The sample analyzer according to claim 5, wherein: The sample to be tested is a blood sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: According to the forward scattered light intensity information and the fluorescence intensity information in the optical information, the nucleated red blood cell particle group and at least one particle group of the basophil subpopulation in the sample to be tested are distinguished, and the at least one particle group is counted.

17. The sample analyzer according to claim 6, wherein: The sample to be tested is a blood sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: According to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, at least one particle group of the nucleated red blood cell particle group and the basophil subgroup in the sample to be tested is distinguished.

18. The sample analyzer according to claim 6, wherein: The sample to be tested is a blood sample; Wherein, the control device is configured to further perform the following steps when the computer program is executed by the processor: According to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, the nucleated red blood cell particle group and at least one particle group of the basophil subpopulation in the sample to be tested are distinguished, and the at least one particle group is counted.

19. The sample analyzer according to claim 3, wherein: The hemolysis reagent has a pH value of 6.5-7.

5.

20. The sample analyzer according to claim 19, wherein: The hemolysis reagent has a pH value of 7.

0.

21. The sample analyzer according to claim 2, wherein: The hemolysis reagent has a pH value of 2.0-4.

0.

22. The sample analyzer according to claim 21, wherein: The hemolysis reagent has a pH value of 3.

0.

23. The sample analyzer according to claim 1, wherein: The control device is configured to further perform the following steps when the computer program is executed by the processor: The cryptococcal particle population in the sample to be tested is counted.

24. The sample analyzer according to claim 23, wherein: The control device is configured to further perform the following steps when the computer program is executed by the processor: When the count value of the cryptococcal particle group exceeds a predetermined value, it indicates that cryptococcal infection exists in the sample to be tested.

25. A sample analyzer, comprising: A sampling device, comprising a pipette with a pipette nozzle and a driving device for driving the pipette to quantitatively suck a sample to be tested through the pipette nozzle; A sample preparation device, comprising at least one reaction pool and a reagent supply unit, wherein the at least one reaction pool is used to receive the sample to be tested sucked by the sampling device, and the reagent supply unit is configured to provide a hemolysis reagent to the at least one reaction pool, so that the sample to be tested sucked by the sampling device and the hemolysis reagent provided by the reagent supply unit are mixed in the at least one reaction pool to prepare a sample to be tested; An optical detection device, comprising a light source, a flow chamber, a first scattered light detector and a second scattered light detector, wherein the particles of the sample to be tested can pass through the flow chamber one by one, the light emitted by the light source irradiates the particles in the flow chamber to generate optical information, the first scattered light detector is used to collect forward scattered light intensity information, and the second scattered light detector is used to collect side scattered light intensity information, wherein the optical information includes the forward scattered light intensity information and the side scattered light intensity information; and A control device electrically connected to the optical detection device and comprising a processor and a storage medium storing a computer program, wherein the control is configured to perform the following steps when the computer program is executed by the processor: acquiring the optical information from the optical detection device, and generating a two-dimensional or three-dimensional scatter plot according to the optical information, obtaining a cryptococcal particle characteristic region according to the two-dimensional or three-dimensional scatter plot, and identifying particles in the cryptococcal particle characteristic region as cryptococcal particles, Wherein, in the two-dimensional or three-dimensional scatter plot, the forward scattered light intensity of the cryptococcal particles shows a trend extending from small to large.

26. The sample analyzer according to claim 25, wherein: The sample to be tested is a blood sample, and the control device is configured to further perform the following steps when the computer program is executed by the processor: Leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils are distinguished based on the optical information.

27. The sample analyzer according to claim 25, wherein: The sample to be tested is a blood sample, and the control device is configured to further perform the following steps when the computer program is executed by the processor: White blood cell subpopulations including lymphocytes, monocytes, neutrophils and eosinophils are distinguished according to the optical information, and the distinguished white blood cell subpopulations are counted.

28. The sample analyzer according to claim 25, wherein: The reagent supply section is configured to provide a hemolytic reagent and a fluorescent reagent to the at least one reaction pool, so that the sample to be tested drawn by the sampling device is mixed with the hemolytic reagent and the fluorescent reagent provided by the reagent supply section in the reaction pool to prepare a sample to be tested. The optical detection device also includes a fluorescence detector for collecting fluorescence intensity information, and the optical information further includes the fluorescence intensity information.

29. The sample analyzer according to claim 28, wherein: The control device is configured to perform the following steps when the computer program is executed by the processor: Controlling the sample preparation device to prepare a first sample to be tested by mixing a first portion of the sample to be tested with a first hemolysis reagent and a first fluorescent reagent to obtain the first sample to be tested; Controlling the optical detection device to detect the first sample to be tested to obtain first optical information of each particle in the first sample to be tested; Differentiate and count cryptococcal particles in the first test sample according to the first optical information to obtain a first cryptococcal particle count value; Controlling the sample preparation device to prepare a second sample to be tested by mixing a second portion of the sample to be tested with a second hemolysis reagent different from the first hemolysis reagent to obtain the second sample to be tested; Controlling the optical detection device to detect the second sample to be tested to obtain second optical information of each particle in the second sample to be tested; Separate and count the cryptococcal particles in the second test sample according to the second optical information to obtain a second cryptococcal particle count value; and According to the first cryptococcal particle count value and the second cryptococcal particle count value, it is determined whether there is cryptococcal infection in the sample to be tested.

30. The sample analyzer according to claim 29, wherein: The first optical information includes forward scattered light intensity information and fluorescence intensity information.

31. The sample analyzer according to claim 29, wherein: The first optical information includes forward scattered light intensity information, side scattered light intensity information and fluorescence intensity information.

32. The sample analyzer according to any one of claims 29 to 31, wherein: The second optical information includes forward scattered light intensity information and side scattered light intensity information.

33. The sample analyzer according to any one of claims 29 to 31, wherein: The control device is configured to perform the following steps when controlling the sample preparation device to prepare the second sample to be tested: Controlling the sample preparation device to prepare a second sample to be tested by mixing a second portion of the sample to be tested with a second hemolytic reagent different from the first hemolytic reagent and a second fluorescent reagent different from the first fluorescent reagent to obtain the second sample to be tested; The second optical information includes forward scattered light intensity information, side scattered light intensity information and fluorescence intensity information.

34. The sample analyzer according to any one of claims 29 to 31, wherein: The first hemolytic reagent has a pH value of 6.5-7.5; and / or the second hemolytic reagent has a pH value of 2.0-4.

0.

35. The sample analyzer according to claim 34, wherein: The first hemolytic reagent has a pH value of 7.0; and / or the second hemolytic reagent has a pH value of 3.

0.

36. The sample analyzer according to any one of claims 29 to 31, wherein: The control device is configured to perform the following steps when determining whether there is cryptococcal infection in the sample to be tested: When the difference between the first cryptococcal particle count value and the second cryptococcal particle count value is within a preset range, it is determined that cryptococcal infection exists in the sample to be tested.

37. A method for detecting cryptococcus in a sample, the method comprising the following steps: Processing the sample to be tested to obtain the sample to be tested, wherein the processing of the sample to be tested includes mixing the sample to be tested with a hemolysis reagent; Allow the particles in the sample to be tested to pass through an optical detector one by one to obtain optical information of each particle in the sample to be tested, wherein the optical information at least includes forward scattered light intensity information; Differentiating cryptococcal particles in the sample to be tested according to the optical information includes: generating a two-dimensional or three-dimensional scatter plot according to the optical information, obtaining a cryptococcal particle characteristic region according to the two-dimensional or three-dimensional scatter plot, and identifying particles in the cryptococcal particle characteristic region as cryptococcal particles. Wherein, in the two-dimensional or three-dimensional scatter plot, the forward scattered light intensity of the cryptococcal particles shows a trend extending from small to large.

38. The method of claim 37, wherein: The optical information further includes side scattered light intensity information.

39. The method of claim 37, wherein: The processing of the sample to be tested further comprises: mixing the sample to be tested with a fluorescent reagent, Wherein, in the test sample, the capsule of the cryptococcus is destroyed, the inner core material of the bacterial body is stained by the fluorescent reagent, and the optical information further includes side scattered light intensity information, or further includes side scattered light intensity information and fluorescence intensity information; or Wherein, in the test sample, the capsule of the cryptococcus remains basically intact, the inner core material of the bacteria basically cannot be stained by the fluorescent reagent, and the optical information further includes fluorescence intensity information, or further includes fluorescence intensity information and side scattered light intensity information.

40. The method of claim 39, wherein: The sample to be tested is a body fluid sample, and the method further comprises: At least one particle group among the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group, and the multinuclear cell particle group is distinguished according to the side scattered light intensity information and the fluorescence intensity information in the optical information.

41. The method of claim 39, wherein: The sample to be tested is a body fluid sample, and the method further comprises: According to the side scattered light intensity information and the fluorescence intensity information in the optical information, at least one particle group among the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group, and the multinuclear cell particle group is distinguished, and the at least one particle group is counted.

42. The method of claim 39, wherein: The sample to be tested is a body fluid sample, and the method further comprises: At least one particle group among the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group, and the multinuclear cell particle group is distinguished according to the forward scattered light intensity information, the side scattered light intensity information, and the fluorescence intensity information in the optical information.

43. The method of claim 39, wherein: The sample to be tested is a body fluid sample, and the method further comprises: According to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, at least one particle group among the white blood cell particle group, the nucleated cell particle group, the mononuclear cell particle group and the multinuclear cell particle group is distinguished, and the at least one particle group is counted.

44. A method according to any one of claims 40 to 43, wherein: The sample to be tested is a cerebrospinal fluid sample.

45. The method of claim 37 or 38, wherein: The sample to be tested is a blood sample, and the method further comprises: According to the forward scattered light intensity information and the side scattered light intensity information in the optical information, leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils are distinguished.

46. ​​The method of claim 37 or 38, wherein: The sample to be tested is a blood sample, and the method further comprises: According to the forward scattered light intensity information and the side scattered light intensity information in the optical information, leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils are distinguished, and the distinguished leukocyte subpopulations are counted.

47. The method of claim 39, wherein: The sample to be tested is a blood sample, and the method further comprises: Differentiating the leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils and / or differentiating the immature granulocyte population according to the side scattered light intensity information and the fluorescence intensity information in the optical information, or counting the differentiated leukocyte subpopulations and / or immature granulocyte population; or According to the forward scattered light intensity information and the fluorescence intensity information in the optical information, the nucleated red blood cell particle group and at least one particle group of the basophil subpopulation in the sample to be tested are distinguished, or the at least one particle group is counted.

48. The method of claim 39, wherein: The sample to be tested is a blood sample, and the method further comprises: Differentiating leukocyte subpopulations including lymphocytes, monocytes, neutrophils and eosinophils and / or differentiating immature granulocyte populations according to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, or counting the differentiated leukocyte subpopulations and / or immature granulocyte populations; or According to the forward scattered light intensity information, the side scattered light intensity information and the fluorescence intensity information in the optical information, the nucleated red blood cell particle group and at least one particle group of the basophil subpopulation in the sample to be tested are distinguished, or the at least one particle group is counted.

49. The method according to any one of claims 37 to 39, wherein: The method further comprises: The cryptococcal particle population in the sample to be tested is counted.

50. The method of claim 49, wherein: The method further comprises: When the count value of the cryptococcal particle group exceeds a predetermined value, it indicates that cryptococcal infection exists in the sample to be tested.

51. The method according to any one of claims 37 to 39, wherein: The hemolytic reagent has a pH value of 2.0-4.0; or the hemolytic reagent has a pH value of 6.5-7.

5.

52. The method of claim 51, wherein: The hemolytic reagent has a pH value of 3.0; or the hemolytic reagent has a pH value of 7.

0.

53. A method for detecting cryptococcus in a sample, the method comprising the following steps: Processing a first portion of the sample to be tested to obtain a first sample to be tested, wherein the processing of the first portion of the sample to be tested includes mixing the first portion of the sample with a first hemolysis reagent and a first fluorescent reagent; Allowing particles in the first sample to be tested to pass through an optical detector one by one to obtain first optical information of each particle in the first sample to be tested; Differentiate and count cryptococcal particles in the first test sample according to the first optical information to obtain a first cryptococcal particle count value; Processing a second portion of the sample to be tested to obtain a second sample to be tested, wherein the processing of the second portion of the sample to be tested includes mixing the second portion of the sample with a second hemolysis reagent different from the first hemolysis reagent; Allowing particles in the second sample to be tested to pass through the optical detector one by one to obtain second optical information of each particle in the second sample to be tested; Differentiate and count cryptococcal particles in the second test sample according to the second optical information to obtain a second cryptococcal particle count value; According to the first cryptococcal particle count value and the second cryptococcal particle count value, determining whether there is cryptococcal infection in the sample to be tested, The first optical information and the second optical information respectively include forward scattered light intensity information, wherein the forward scattered light intensity of the cryptococcal particles in a two-dimensional or three-dimensional scatter plot generated according to the first optical information and the second optical information respectively shows a trend extending from small to large.

54. The method of claim 53, wherein: The first optical information further includes fluorescence scattered light intensity information.

55. The method of claim 54, wherein: The first optical information further includes side scattered light intensity information and fluorescence intensity information.

56. A method according to any one of claims 53 to 55, wherein: The second optical information further includes side scattered light intensity information.

57. The method according to any one of claims 53 to 55, wherein: The processing of the second portion of the sample to be tested comprises mixing the second portion of the sample with a second hemolytic reagent different from the first hemolytic reagent and a second fluorescent reagent different from the first fluorescent reagent; Wherein, the second optical information further includes side scattered light intensity information and fluorescence intensity information.

58. The method according to any one of claims 53 to 55, wherein: The first hemolytic reagent has a pH value of 6.5-7.5; and / or the second hemolytic reagent has a pH value of 2.0-4.

0.

59. The method of claim 58, wherein: The first hemolytic reagent has a pH value of 7.0; and / or the second hemolytic reagent has a pH value of 3.

0.

60. The method according to any one of claims 53 to 55, wherein: The step of judging whether there is cryptococcal infection in the sample to be tested according to the first cryptococcal particle count value and the second cryptococcal particle count value includes: When the difference between the first cryptococcal particle count value and the second cryptococcal particle count value is within a preset range, it is determined that cryptococcal infection exists in the sample to be tested.

61. A computer-readable storage medium having a computer program stored thereon, characterized in that: When the computer program is executed by a processor, the steps of the method according to any one of claims 37 to 60 are implemented.